Raymond Deshaies, Ph.D., joined our Board in July 2025. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen’s capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein design to biologics discovery. Prior to joining Amgen in 2017, he was a professor in the Division of Biology and Biological Engineering (BBE) at the California Institute of Technology (Caltech), where he remains an external affiliate. During his tenure at Caltech, he also served as executive officer of the BBE Division. In 2003, Dr. Deshaies co-founded Proteolix, which discovered carfilzomib, a selective proteasome inhibitor for the treatment of patients with advanced multiple myeloma, marketed as KYPROLIS®. He later founded Cleave Biosciences, which was focused on modulating protein homeostasis pathways. Dr. Deshaies co-authored over 170 scientific papers and is an international leader in the fields of protein homeostasis and targeted protein degradation. He was named an investigator of the Howard Hughes Medical Institute in 2000 and elected to the American Academy of Arts and Sciences and the National Academy of Sciences in 2011 and 2016, respectively. Dr. Deshaies earned his B.S. in biochemistry from Cornell University and his Ph.D. from the University of California, Berkeley. He completed postdoctoral research at Berkeley and at the University of California, San Francisco. We believe Dr. Deshaies’ experience in biotechnology company leadership qualifies him to serve on our Board.